MGRX Mangoceuticals, Inc.
$0.40▲ +4.62%
Healthcare
Other
After hours
$0.40▼ -0.62%
Sep 11, 7:33 PM ET
Volume 287.8K
Avg Volume (10D) 318.4K
Key Metrics & Fundamentals
Market Cap
$8.69M
P/E Ratio
–
Div Yield
–%
52W Range
0.16 - 2.75
% vs 50 MA
-9.32%
% vs 200 MA
-21.18%
RSI-14
46.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.49
Free Cash Flow
-$260,506
Gross Rev
$68,757
Gross Profit
$44,215
EBITDA
-$738,214
COGS
$24,542
Operating Exp
$1.08M
Operating Income
-$1.03M
EBIT
-$1.03M
Pretax Income
-$1.31M
Net Income
-$1.31M
EPS (Diluted)
-0.09
Price & Volume History
Loading chart…
Recent News
Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
GlobeNewswire · Aug 13, 2026 8:05 PM
Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
GlobeNewswire · Aug 5, 2026 8:05 PM
Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
GlobeNewswire · Aug 4, 2026 8:05 PM
BC-Most Active Stocks
Associated Press · Jul 31, 2026 2:30 PM
Mangoceuticals Reports Merger Deal With Nuclea Energy
MT Newswires · Jul 30, 2026 3:07 PM
Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
TMX Newsfile · Jul 30, 2026 2:35 PM
Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
GlobeNewswire · Jul 30, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See MGRX's money flow as a full page
Social Sentiment
No Reddit posts found for MGRX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.